Genomic Screening for Hereditary Erythrocytosis and Related Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-31

Study Completion Date

2020-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Unexplained polycythemias are rare diseases, and therefore, the collection of data inherent to these diseases will not only improve their characterisation, but also allow stratification according to the risks and the course of the disease. The objective of this project is to constitute a database on the disease which will allow us to better understand it and in due course improve its management.

The GENRED project thus bears uniquely on the collection of information, which will be gathered throughout the usual management of patients for this type of disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Registry of Congenital Dyserythropoietic Anemia

NCT03983629

Congenital Dyserythropoietic Anemia

UNKNOWN

POlycythemia, Proteins and ErYthropoiesis

NCT06905106

Erythropoiesis

RECRUITING

Molecular Biology of Polycythemia and Thrombocytosis

NCT00722527

Polycythemia Thrombocytosis

RECRUITING

Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.

NCT05440838

Myeloproliferative Neoplasm

NOT_YET_RECRUITING

Hereditary Spherocytosis and Vascular Function

NCT04451785

Hereditary Spherocytosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Erythrocytosis/Idiopathic Erythrocytosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The characteristics of the patients included in the database will be described in terms of numbers and percentages for qualitative variables and in terms of means and standard deviations or medians and interquartile intervals for quantitative variables.

Exclusion Criteria

The first step will be to exclude acquired secondary (pulmonary, renal and cardiac) or acquired primary (polycythemia vera due to JAK2 mutations) causes. The family history and the determination of serum EPO levels are very useful in the decision regarding which molecular tests should be performed first.

* patients without absolute erythrocytosis (i.e. without an increased red cell mass \>125% of mean predicted value, or if the haematocrit is \<60% in males or \<56% in females.
* erythrocytosis related to polycythemia vera according to the 2008 WHO (World Health Organization) criteria
* Secondary erythrocytosis related to an obvious cause (renal lesions, chronic lung or heart diseases, endocrine lesions, miscellaneous tumours producing EPO, drugs such as androgens, hepatic lesions…)
* Low venous blood p50: the determination of p50 (percentage at which Hb is half saturated with oxygen) is very helpful is establishing the presence of a haemoglobin variant with high oxygen affinity or a rare 2,3-diphosphoglycerate (2,3-DPG) deficiency. In such a situation, a specific HBB, HBA1 and HBA2 mutation will be screened for using Sanger sequencing (these genes are not included in NGS analysis because of redundancy of pseudogenes).

In order to rule out non-informative erythrocytosis cases, a form including mandatory further tests must be filled in for a selection step. The required tests are: complete blood counts

* Blood electrolytes
* Arterial and venous gazes
* Serum erythropoietin dosage
* Liver function tests
* JAK2 mutations (both V617F and exon 12)
* Bone marrow aspirate and/or biopsy and/or endogenous BFU-E culture
* Abdominal ultrasound
* Lung function tests

Eligible Sex

ALL

Accepts Healthy Volunteers

No